[Click eStock] "Plasmapp Ramps Up New Product Launches... Earnings Rebound Expected in 2027" View original image

Plasmapp is aiming to improve its performance next year by launching new products. After securing domestic approval for a new low-temperature sterilizer, the company is also preparing to launch a root canal treatment device. Analysts say its financial stability has also improved as its largest shareholder, Dreamtech, strengthened its control.


Independent research firm Value Finder published a company analysis report on Plasmapp on November 19, highlighting the potential for a turnaround in 2027 as new product launches gather momentum. It did not issue an investment rating or a target price.


Founded in 2015 and listed on the KOSDAQ market in 2022, Plasmapp specializes in medical devices based on bioplasma technology. As of the third quarter of this year, ACTILINK and STERLINK accounted for 61.1% of revenue, consumables for 35.8%, and other products for 3.1%. Consolidated revenue in the third quarter was 1.6 billion won, down 24.1% from the same period a year earlier, while the company continued to post an operating loss of 2.1 billion won.


Jeon Woobin, an analyst at Value Finder, said the weak third-quarter results were due to temporary factors. He explained that the results were affected by a high base of comparison following concentrated shipments to partners such as MegaGen Implant in the first half, as well as a production gap caused by the partial relocation of outsourced manufacturing facilities.


"The gap in new product launches is expected to narrow starting in the fourth quarter," Jeon said. "The 30-liter STERI 700 low-temperature sterilizer received approval from the Ministry of Food and Drug Safety this month, and initial mass production is expected to begin." The STERI 700 has a chamber about four times larger than those of the company's existing small sterilizers, and is expected to help expand its customer base beyond dentistry into fields such as ophthalmology and orthopedics. The company is also pursuing U.S. Food and Drug Administration (FDA) 510(k) clearance and European CE certification to enter global markets.


The company also plans to launch Plasmapp Endo, a root canal treatment device. The basic model has completed its technical documentation review, and domestic certification is expected by the end of the year. The model equipped with a micro camera is targeted for launch in the first half of 2027. Taking into account a U.S. supply contract with QMED worth 3.5 billion won, which includes 90 STERI 700 units, analysts expect revenue from new products to gain momentum next year.


Dreamtech's strengthened control as Plasmapp's largest shareholder was cited as a positive factor for the company's finances. In August, Dreamtech was the sole participant in a 7 billion won third-party allotment paid-in capital increase, raising its stake in Plasmapp from 27.7% to 48.3%. Including open-market purchases by its affiliate Namuga, the stake held by the largest shareholder and related parties rose to 69.8%.



"Cash and cash equivalents stood at around 3.1 billion won at the end of the third quarter," Jeon said. "Once production normalizes in the fourth quarter and initial mass production of the STERI 700 begins, we believe the company will not need additional external funding for the time being." He added, "It is worth watching how quickly earnings improve following the start of STERI 700 sales."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing